Article thumbnail

Contrast-enhancement cardiac magnetic resonance imaging beyond the scope of viability

By M. A. G. M. Olimulder, M. A. Galjee, J. van Es, L. J. Wagenaar and C. von Birgelen

Abstract

The clinical applications of cardiovascular magnetic resonance imaging with contrast enhancement are expanding. Besides the direct visualisation of viable and non-viable myocardium, this technique is increasingly used in a variety of cardiac disorders to determine the exact aetiology, guide proper treatment, and predict outcome and prognosis. In this review, we discuss the value of cardiovascular magnetic resonance imaging with contrast enhancement in a range of cardiac disorders, in which this technique may provide insights beyond the scope of myocardial viability

Topics: Review Article
Publisher: Bohn Stafleu van Loghum
OAI identifier: oai:pubmedcentral.nih.gov:3087018
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model.
  2. (2011). Assessment of myocardial viability with 3D MRI at 3T.
  3. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach.
  4. Cardiac magnetic resonance in Chagas’ disease. Artif Organs.
  5. (2005). Cardiac tumours: diagnosis and management. Lancet Oncol.
  6. (2008). Cardiomyopathy: magnetic resonance imaging evaluation. Semin Roentgenol.
  7. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis.
  8. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology.
  9. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy.
  10. Chagas disease is characterised by specific pattern and location of myocardial delayed enhancement MRI. J Cardiovasc Magn Reson.
  11. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance.
  12. (2004). Comparison of echo and MRI in the imaging evaluation of intracardiac masses. Cardiovasc Interv Radiol.
  13. Contrast enhancedcardiovascular magnetic resonance imaging in patients with pulmonary hypertension.
  14. Contrast-enhanced MR imaging of the heart: overview of the literature.
  15. (2007). Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease. Heart Lung Circ.
  16. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease.
  17. Delayed enhancement MR imaging: utility in myocardial assessment.
  18. Detection of myocardial damage in patients with sarcoidosis.
  19. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria.
  20. (1994). Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the
  21. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging.
  22. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches.
  23. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction.
  24. (2011). Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?
  25. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury.
  26. Gadolinium-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging of dilated cardiomyopathy: clinical significance of abnormally high signal intensity of left ventricular myocardium.
  27. Images in cardiovascular medicine. Contrast-enhanced magnetic resonance imaging of a patient with chloroquine-induced cardiomyopathy confirmed by endomyocardial biopsy.
  28. Images in cardiovascular medicine. Magnetic resonance contrast enhancement of iatrogenic septal myocardial infarction in hypertrophic cardiomyopathy.
  29. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction.
  30. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia.
  31. (2009). Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging.
  32. Intracardiac thrombi: diagnostic accuracy needs to be improved!
  33. Ischaemic and nonischaemic cardiomyopathies–cardiac MRI appearances with delayed enhancement.
  34. (2011). Letter by Pieroni et al regarding article, “Contrast-enhanced magnetic resonance imaging of a 244
  35. Magnetic resonance imaging of targeted catheter-based implantation of myogenic precursor cells into infarcted left ventricular myocardium.
  36. MR imaging of cardiac tumors.
  37. MRI for the assessment of myocardial viability.
  38. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity.
  39. Myocardial salvage by CMR correlates with LV remodeling and early ST-segment resolution in acute myocardial infarction.
  40. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy.
  41. No-reflow’ after acute myocardial infarction: direct visualisation of microvascular o b s t r u c t i o nb yg a d o l i n i u m - enhanced CMR.
  42. Nontransmural scar detected by magnetic resonance imaging and origin of ventricular tachycardia in structural heart disease. Pacing Clin Electrophysiol. 2009;32 Suppl 1:S52–6.
  43. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis.
  44. Quantitative myocardial infarction on delayed enhancement MRI. Part I: animal validation of an automated feature analysis and combined thresholding infarct sizing algorithm.
  45. Relation between myocardial edema and myocardial mass during the acute and convalescent phase of myocarditis—a CMR study.
  46. (2005). Restrictive and infiltrative cardiomyopathies.
  47. (2006). Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation.
  48. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells.
  49. Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR).
  50. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging
  51. (2002). Stem cells for myocardial regeneration. Circ Res.
  52. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence.
  53. (2009). The characteristics and distribution of the scar tissue predict ventricular tachycardia in patients with advanced heart failure. Pacing Clin Electrophysiol.
  54. The emerging role of magnetic resonance imaging in the diagnosis and management of pulmonary hypertension.
  55. (2006). The evolving role of cardiovascular magnetic resonance imaging in nonischemic cardiomyopathy.
  56. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy.
  57. The role of cardiac magnetic resonance imaging in differentiating the underlying causes of left ventricular hypertrophy.
  58. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.
  59. Time course of eosinophilic myocarditis visualized by CMR.
  60. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.
  61. Universal definition of myocardial infarction.
  62. Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease.
  63. Value of MRI in patients with a clinical suspicion of acute myocarditis.
  64. Various findings of cardiac thrombi
  65. Ventricular arrhythmia in coronary artery disease: limits of a risk stratification strategy based on the ejection fraction alone and impact of infarct localization.